Nyxoah SA NYXH 深 滬
等待開盤 03-27 09:30:00 美东时间
3.07
-0.100
-3.15%
華盛通- 最 高3.13
- 今 開3.13
- 成交量 8.15万股
- 最 低 3.0572
- 昨 收 3.17
- 總市值 1.34亿
- 52周最高 8.64
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 3.02
- 委 比 87.10%
- 總股本 4366.24万
- 歷史最高 37.00
- 量 比 1.40
- 振 幅 2.30%
- 歷史最低 3.02
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Stifel Maintains Buy on Nyxoah, Lowers Price Target to $10
Stifel analyst Jonathan Block maintains Nyxoah (NASDAQ:NYXH) with a Buy and lowers the price target from $11 to $10.
03-21 00:21
电话会总结 ｜ Nyxoah(NYXH)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Nyxoah业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2025年第四季度业绩：** - 总收入：630万欧元（扣除70万欧元递延收入后，净收入为560万欧元） - 毛利率：64% - 运营亏损：1,860万欧元 - 美国市场净收入：约350万欧元 **2025年全年业绩：** - 总收入：1,100万欧元（扣除100万欧元递延收入后，净收入为1,000万欧元） - 毛利率：63% - 运营亏损：8,350万欧元 - 现金及现金等价物：4,800万欧元（截至2025年12月31日） - 季度现金消耗率：约2,000万欧元 ##
03-20 12:01
Nyxoah Q4 EPS $(0.68) Misses $(0.65) Estimate, Sales $6.570M Miss $6.740M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 38.78 percent decrease over losses of $(0.49) per share from the same
03-20 04:13
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Nyxoah reported strong financial and operating results for Q4 and full year 2025, driven by the successful U.S. commercialization of its Genio system. Q4 gross revenue was €6.3 million, up 347% YoY, with net revenue of €5.6 million. Full year gross revenue reached €11.0 million, up 122% YoY, with net revenue of €10.0 million. The Company ended 2025 with €48 million in cash and had trained 145 surgeons and activated 57 U.S. accounts since its Augu...
03-19 20:10
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Publication relating to transparency notification
Nyxoah SA announced on March 13, 2026, that it received a transparency notification from BNP Paribas Asset Management SA. As of March 9, 2026, BNP Paribas Asset Management Europe SAS holds 1,307,817 voting rights, representing 3.00% of the total voting rights (43,662,403). The notification indicates a downward crossing of the 3% threshold and clarifies the chain of controlled entities and voting rights exercise.
03-13 21:30
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Nyxoah SA, a medical technology company treating Obstructive Sleep Apnea (OSA), will release its 2025 fourth-quarter and full-year financial results on March 19, 2026. The company, which developed the Genio system—a leadless and battery-free neurostimulation therapy for OSA—will discuss the results during a conference call at 10:30pm CET / 4:30pm ET. Interested parties can join via a webcast or telephone. The Genio system has received European CE...
03-05 21:05
Publication relating to transparency notifications
On February 27, 2026, Nyxoah SA announced receiving a transparency notification from Robert Taub and BMI Estate, indicating they now hold 9.99% of voting rights (4,360,800) as of February 20, 2026, due to a passive crossing of the 10% threshold. This includes 4,310,800 shares linked to securities and 50,000 equivalent financial instruments. The notification was submitted by a parent undertaking or controlling person, with BMI Estate partially own...
02-27 21:30
